Drug Profile
C 1311
Alternative Names: C-1311; Imidacrine; Imidazoloacridine; NSC 645809; Symadex; Symadex Pathfinder; XLS-002Latest Information Update: 16 Jun 2008
Price :
$50
*
At a glance
- Originator University of Bradford
- Developer Antisoma
- Class Aminoacridines; Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Lymphoid leukaemia; Multiple sclerosis; Rheumatoid arthritis; Solid tumours; Ulcerative colitis
Most Recent Events
- 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
- 03 Jun 2008 Final adverse events data from a phase I trial in patients with advanced solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
- 03 Jun 2008 Efficacy data from a phase II trial in advanced breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)